Innate Pharma (XPAR:IPH) Inventory Turnover: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:IPH Innate Pharma SA XPAR:IPH
32 GF Score
Price €1.58
GF Value €0.13
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Innate Pharma Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Innate Pharma's Cost of Goods Sold for the six months ended in Jun. 2026 was € Mil. Innate Pharma's Average Total Inventories for the quarter that ended in Jun. 2026 was €0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Innate Pharma's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.00.

Innate Pharma  (XPAR:IPH) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Innate Pharma's Days Inventory for the six months ended in Jun. 2026 is calculated as:

Days Inventory =Average Total Inventories (Q: Jun. 2026 )/Cost of Goods Sold (Q: Jun. 2026 )*Days in Period
=0/*365 / 2
=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Innate Pharma's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Jun. 2026 ) / Revenue (Q: Jun. 2026 )
=0 / 3.115
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Innate Pharma Inventory Turnover Related Terms

Innate Pharma Inventory Turnover Historical Data

* Premium members only.

The historical data trend for Innate Pharma's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innate Pharma Inventory Turnover Chart

Innate Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only

Innate Pharma Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only
XPAR:IPH
32GF Score
Innate Pharma SA XPAR:IPH
Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Innate Pharma Inventory Turnover Calculation

Innate Pharma's Inventory Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Inventory Turnover (A: Dec. 2025 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2025 ) / ((Total Inventories (A: Dec. 2024 ) + Total Inventories (A: Dec. 2025 )) / count )
= / ((0 + 0) / 1 )
= / 0
=N/A

Innate Pharma's Inventory Turnover for the quarter that ended in Jun. 2026 is calculated as

Inventory Turnover (Q: Jun. 2026 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Jun. 2026 ) / ((Total Inventories (Q: Dec. 2025 ) + Total Inventories (Q: Jun. 2026 )) / count )
= / ((0 + 0) / 1 )
= / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Innate Pharma (XPAR:IPH) Overvalued in 2026?

Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued. The current stock price of €1.58 is trading 1115.4% above its estimated GF Value™ of €0.13. GuruFocus considers Innate Pharma to be Significantly Overvalued.

Key valuation signals for XPAR:IPH:

  • Inventory Turnover:
  • GF Value™: €0.13 vs. price of €1.58 (1115.4% above fair value)
  • GF Score™: 32/100 with 6 warning signs

No single metric tells the full story. See the XPAR:IPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Innate Pharma Business Description

Address 117, Avenue de Luminy, Marseille, FRA, 13009
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
32GF Score

Get the complete analysis for XPAR:IPH

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.58
Price
€0.13
GF Value